

- **Full Name:** Sun Young Rha
 - **Current Position & Affiliation:** Professor of Medical Oncology, Internal Medicine, Yonsei Cancer Center, Yonsei University Health System
Director of Songdang Institute for Cancer Research, Yonsei University College of Medicine
 - **Country:** Republic of Korea
-

- **Educational Background:**

- MD, PhD at Yonsei University College of Medicine
- Clinical and Research Fellow of Medical Oncology at Yonsei Cancer Center, Yonsei University Health System
- Post-doctoral fellow at Cancer Therapy and Research Center
- Institute for Drug Development
- The University of Texas Health Science Center at San Antonio

- **Professional Experience:**

- Assistant professor at the Cancer Metastasis Research Center, Yonsei Cancer Center
- Associate Professor, Medical Oncology, Internal Medicine, Yonsei University college of Medicine
- Chief, Division of Genomics and Translational Research, Cancer Metastasis Research Center, Yonsei University College of Medicine
- Director, Human research Protection Center, Severance Hospital
- Director of Songdang Institute for Cancer Research, Yonsei University College of Medicine

- **Professional Organizations:**

- Chair, Academic Committee of Korean Cancer Society (KCA)
- Executive Board Member, chair of Gastric Cancer Committee, Korean Cancer Study Group
- Vice President of Korean Gastric Cancer Society
- Vice President of Korea Genome Organization
- Chair, Planning Committee of Korean Association of IRB
- Board member of Korean Society of Medical Oncology

- **Main Scientific Publications:**

1. Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Advanced Gastric or Gastroesophageal Junction Cancer, Chang Gon Kim, Minkyu Jung, Hyo Song Kim, Choong-kun Lee, Hei-Cheul Jeung, Dong-Hoe Koo, Woo Kyun Bae, Dae Young Zang, Bum Jun Kim, Hyunki Kim, MD, Un-Jung Yun, Jingmin Che, Sejung Park, Tae Soo Kim, Woo Sun Kwon, Juin Park, Sang Woo Cho, Chung Mo Nam, Hyun Cheol Chung, and Sun Young Rha. JCO 2023 June 26

2. Breakthroughs in the Systemic Treatment of HER2-Positive Advanced/Metastatic Gastric Cancer: From Singlet Chemotherapy to Triple Combination. Sun Young Rha, Hyun Cheol Chung. *J Gastric Cancer*. 2023 Jan;23(1):224-249. doi: 10.5230/jgc.2023.23.e6.
3. A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer. Lee CK, Rha SY, Kim HS, Jung M, Kang B, Che J, Kwon WS, Park S, Bae WK, Koo DH, Shin SJ, Kim H, Jeung HC, Zang DY, Lee SK, Nam CM, Chung HC. *Nat Commun*. 2022 Oct 12;13(1):6002. doi: 10.1038/s41467-022-33267-z.
4. First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors. Filip Janku, Seung-Hoon Beom, Yong Wha Moon, Tae Won Kim, Young G Shin, Dong-Seok Yim, Gun Min Kim, Hyo Song Kim, Sun Young Kim, Jae-Ho Cheong, Young Woo Lee, Barb Geiger, Sanghee Yoo, Archie Thurston, Dean Welsch, Marc S Rudoltz, Sun Young Rha. *Invest New Drugs*. 2022 Oct;40(5):1001-1010.
5. Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial. Sumanta K Pal, Javier Puente, Daniel Y C Heng, Hilary Glen, Piotr Koralewski, Daniil Stroyakovskiy, Boris Alekseev, Francis Parnis, Daniel Castellano, Tudor Ciuleanu, Jae Lyun Lee, Kaisa Sunela, Karen O'Hara, Terri A Binder, Lixian Peng, Alan D Smith, Sun Young Rha. *Eur Urol*. 2022 Sep;82(3):283-292.
6. The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients. Lee CK, Chon HJ, Kwon WS, Ban HJ, Kim SC, Kim H, Jeung HC, Chung J, Rha SY. *Genomics Inform*. 2022 Sep;20(3):e29
7. PD-L1 expression and overall survival in Asian and western patients with gastric cancer. Sun Young Rha, Geoffrey Y Ku, Hyo Song Kim, Hyun Cheol Chung, Fatemeh Ghazanfari Amlashi, Dipen Maheshbhai Maru, Carly A Fein, Laura H Tang, Wei Zhou, Ting Wu, Senaka A Peter, David P Kelsen, Jaffer A Ajani. *Future Oncol*. 2022 Jul;18(21):2623-2634.
8. Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition. Sundar R, Huang KK, Kumar V, Ramnarayanan K, Demircioglu D, Her Z, Ong X, Bin Adam Isa ZF, Xing M, Tan AL, Tai DWM, Choo SP, Zhai W, Lim JQ, Das Thakur M, Molinero L, Cha E, Fasso M, Niger M, Pietrantonio F, Lee J, Jeyasekharan AD, Qamra A, Patnala R, Fabritius A, De Simone M, Yeong J, Ng CCY, Rha SY, Narita Y, Muro K, Guo YA, Skanderup AJ, So JBY, Yong WP, Chen Q, Göke J, Tan P. *Gut*. 2022 Jul;71(7):1277-1288.
9. Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16). Bum Jun Kim, Hee-Jung Jee, Sun Young Rha, Hye Sook Han, Min-Hee Ryu, Se Hoon Park, Jong Gwang Kim, Woo Kyun Bae, Keun-Wook Lee, Do-Youn Oh, Ji-Hye Byun, Dong Sook Kim, Young Ju Suh, Hyonggin An, Dae Young Zang. *Gastric Cancer*. 2022 May;25(3):609-618.
10. Inhibition of the bromodomain and extra-terminal family of epigenetic regulators as a promising therapeutic approach for gastric cancer. Sun Kyoung Kang, Hyun Joo Bae, Woo Sun Kwon, Tae Soo Kim, Kyu Hyun Kim, Jihyun Hawang, Juin Park, Hyun Cheol Chung, Sun Young Rha. *Cellular Oncology* 2021 Dec;44(6):1387-1403

11. International Retrospective Cohort Study of Conversion Therapy for Stage IV Gastric Cancer 1 (CONVO-GC-1). Kazuhiro Yoshida , Itaru Yasufuku, Masanori Terashima, Sun Young Rha, Jae Moon Bae, Guoxin Li, Hitoshi Katai, Masahiko Watanabe, Yasuyuki Seto, Sung Hoon Noh, Han- Kwang Yang, Jiafu Ji, Hideo Baba, Yuko Kitagawa, Satoshi Morita, Masahiko Nishiyama, Yasuhiro Kodera. *Ann Gastroenterol Surg.* 2021 Oct 20;6(2):227-240
12. "3G" Trial: An RNA Editing Signature to Guide Gastric Cancer Chemotherapy. An O, Song Y, Ke X, So JB, Sundar R, Yang H, Rha SY, Lee MH, Tay ST, Ong X, Tan ALK, Ng MCH, Tantoso E, Chen L, Tan P, Peng Yong W, Cancer Consortium SG. *Cancer Res.* 2021 May 15;81(10):2788-2798. doi: 10.1158/0008-5472.CAN-20-2872. Epub 2021 Feb 8.
13. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, Kozlov V, Alyasova A, Hong SH, Kapoor A, Alonso Gordoia T, Merchan JR, Winkquist E, Maroto P, Goh JC, Kim M, Gurney H, Patel V, Peer A, Procopio G, Takagi T, Melichar B, Rolland F, De Giorgi U, Wong S, Bedke J, Schmidinger M, Dutcus CE, Smith AD, Dutta L, Mody K, Perini RF, Xing D, Choueiri TK; CLEAR Trial Investigators. *N Engl J Med.* 2021 Apr 8;384(14):1289-1300.
14. Inhibiting casein kinase 2 overcomes paclitaxel resistance in gastric cancer. Jung M, Park KH, Kim HM, Kim TS, Zhang X, Park SM, Beom SH, Kim HS, Cheong JH, Chung HC, Soong J, Lin SC, Rha SY. *Gastric Cancer.* 2019 May 16.
15. Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma. Lee JB, Park HS, Park S, Lee HJ, Kwon KA, Choi YJ, Kim YJ, Nam CM, Cho NH, Kang B, Chung HC, Rha SY. *Cancer Res Treat.* 2019 Apr 16.
16. Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer. Kim C, Chon HJ, Kim JH, Jung M, Nam CM, Kim HS, Kang B, Chung HC, Rha SY. *Eur J Cancer.* 2019 May;112:20-28.